Supported by world-class markets data from Dow Jones and FactSet, and partnering with Automated Insights, MarketWatch Automation brings you the latest, most pertinent content at record speed and with ...

The widespread acceptance of the so-called GLP-1 drugs, Zepbound by Eli Lilly and Wegovy by Novo Nordisk, for weight loss has created a game-changing dynamic for the overall health of the 72% of ...

We recently compiled a list of the 7 Stocks on Jim Cramer’s Radar. In this article, we are going to take a look at where Eli ...

BLOOMINGTON– Lilly Endowment Inc., through the eighth phase of its Giving Indiana Funds for Tomorrow (GIFT VIII) initiative, has awarded a $7,834,000 Community Leadership ...

The Community Foundation of Bloomington and Monroe County (CFBMC) has received a Community Leadership Implementation Grant of $7,394,505 from Lilly Endowment Inc. through ...

Long-term lebrikizumab was effective for atopic dermatitis treatment in patients who did not have adequate response to short-term treatment.

Wafaa Mamilli will join Roche as the company's new Chief Digital Technology Officer in February. This follows expansive roles she has held at Zoetis and at Eli Lilly.

Donald Trump is executing a shock and awe strategy, burying the public in a smoky cloud of flamboyant proposals. Some, like ending birthright citizenship, ...

With new drug development, a significant increase in sales, and high potential with Mounjaro and Zepbound, here’s what we think of Eli Lilly’s stock ...

Eli Lilly and Company (NYSE:LLY), a leading pharmaceutical giant with a market capitalization of $724 billion, has been ...

Healthcare stocks have been under the weather for the past few years, underperforming the broader market’s rally despite ...

Eli Lilly and Company's correction may be coming to an end as the actual demand for its drugs seems to be holding well. Learn more about LLY stock here.